Accelerated Theta Burst in Treatment-Resistant Depression



Status:Recruiting
Conditions:Depression, Depression
Therapuetic Areas:Psychiatry / Psychology
Healthy:No
Age Range:18 - 70
Updated:9/7/2018
Start Date:March 20, 2017
End Date:March 2021
Contact:Claudia K Tischler, BA
Email:ctischler@stanford.edu
Phone:6504988535

Use our guide to learn which trials are right for you!

Accelerated Theta Burst in Treatment-Resistant Depression: A Dose Finding and Biomarker Study

This study evaluates an accelerated schedule of theta-burst stimulation using a transcranial
magnetic stimulation device for treatment-resistant depression. In a double-blind fashion,
half the participants will receive accelerated theta-burst stimulation while half will
receive sham treatment.

Repetitive transcranial magnetic stimulation (rTMS) is an established technology as therapy
for treatment-resistant depression. The approved method for treatment is 10Hz stimulation for
40 min over the left dorsolateral prefrontal cortex (L-DLPFC). This methodology has been very
successful in real world situations. The limitations of this approach include the duration of
the treatment (approximately 40 minutes per treatment session). Recently, researchers have
aggressively pursued modifying the treatment parameters to reduce treatment times with some
preliminary success. This study intents to further modify the parameters to create a more
rapid form of the treatment and look at the change in neuroimaging biomarkers.

Inclusion Criteria:

- Male or female, 18 to 70 years of age.

- Able to provide informed consent.

- Diagnosed with Major Depressive Disorder (MDD) and currently experiencing a Major
Depressive Episode (MDE).

- Participants may currently be on a stable and adequate dose of SSRI antidepressant
therapy. Participants may choose to not be on antidepressant therapy for the study
duration, or to be switched from other classes to a medication from the SSRI class.

- Participants may also have a history of intolerance to at least 2 antidepressant
medications. These patients with the intolerance history will not be required to be
currently taking an antidepressant medication.

- Participants must qualify as "Moderately Treatment Refractory" or "High Treatment
Refractory" using the Maudsley staging method.

- Meet the threshold on the total HAMD21 score of >/=20 at both screening and baseline
visits (Day -5/-14 and Day 0).

- In good general health, as ascertained by medical history.

- If female, a status of non-childbearing potential or use of an acceptable form of
birth control. The form of birth control will be documented at screening and baseline.

- Concurrent hypnotic therapy (e.g., with zolpidem, zaleplon, melatonin, or trazodone)
will be allowed if the therapy has been stable for at least 4 weeks prior to screening
and if it is expected to remain stable.

Exclusion Criteria:

- Female of childbearing potential who is not willing to use one of the specified forms
of birth control during the study.

- Female that is pregnant or breastfeeding.

- Female with a positive pregnancy test at participation.

- Total HAMD score of < 20 at the screen or baseline visits.

- Current diagnosis of a Substance Use Disorder (Abuse or Dependence, as defined by
DSM-IV-TR), with the exception of nicotine dependence, at screening or within six
months prior to screening.

- Current diagnosis of Axis I disorders other than Dysthymic Disorder, Generalized
Anxiety Disorder, Social Anxiety Disorder, Panic Disorder, Agoraphobia, or Specific
Phobia (unless one of these is comorbid and clinically unstable, and/or the focus of
the participant's treatment for the past six months or more).

- History of schizophrenia or schizoaffective disorders, or any history of psychotic
symptoms in the current or previous depressive episodes.

- Any Axis I or Axis II Disorder, which at screening is clinically predominant to their
MDD or has been predominant to their MDD at any time within six months prior to
screening.

- Considered at significant risk for suicide during the course of the study.

- Has a clinically significant abnormality on the screening examination that might
affect safety, study participation, or confound interpretation of study results.

- Participation in any clinical trial with an investigational drug or device within the
past month or concurrent to study participation.

- Any current or past history of any physical condition which in the investigator's
opinion might put the subject at risk or interfere with study results interpretation.

- History of positive screening urine test for drugs of abuse at screening: cocaine,
amphetamines, barbiturates, opiates.

- Current (or chronic) use of opiates.

- History of epilepsy.

- History of rTMS failure with FDA approved rTMS parameters.

- History of any implanted device or psychosurgery for depression.

- History of receiving ECT.

- History of shrapnel or metal in the head or skull.

- "Low Treatment Refractory" using the Maudsley staging method.

- History of cardiovascular disease or cardiac event.

- History of OCD.

- History of autism spectrum disorder.

- History of headache.

- History of independent sleep disorder.
We found this trial at
1
site
291 Campus Drive
Stanford, California 94305
Principal Investigator: Nolan Williams, MD
Phone: 650-498-8535
?
mi
from
Stanford, CA
Click here to add this to my saved trials